Increased risk of renal stones in patients treated with atazanavir

Clinical Infectious Diseases

Volumn 56, Issue 8, 2013, Pages 1186-

  Tattevin, Pierre ^a   Revest, Matthieu ^a   Chapplain, Jean Marc ^a   Ratajczak Enselme, Maja ^a   Arvieux, Cédric ^a   Michelet, Christian ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; LOPINAVIR; PROTEINASE INHIBITOR;

CHOLELITHIASIS; DRUG EXPOSURE; HUMAN; LETTER; NEPHROLITHIASIS; PRIORITY JOURNAL; RISK FACTOR;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KIDNEY CALCULI; MALE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR;

EID: 84875669582     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1211     Document Type: Letter

References (3)

1. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIVinfected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55:1262-9.
2. Rockwood N, Mandalia S, Bower M, Gazzard BNelson M. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir- boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25:1671-3.
3. Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-Associated cholelithiasis: a report of 14 cases. Clin Infect Dis 2012; 55:1270-2.